Immunethep

Immunethep is a private, clinical-stage biotech based in Porto, Portugal, leveraging a proprietary immunomodulatory platform to develop novel anti-infective therapies. The company's pipeline includes both vaccine and monoclonal antibody candidates targeting serious bacterial infections, with programs supported by non-dilutive funding from entities like CARB-X and PACE. With a seasoned leadership team and backing from prominent Portuguese venture capital firms, Immunethep is positioning itself as a key player in the global fight against antimicrobial resistance.

Proprietary Platform of Immunomodulatory Therapies for Infectious Diseases, designed to develop products that boost the host's natural immune response to control bacterial infections.

Immunethep competes in the growing field of novel anti-infectives, facing competition from other biotechs and large pharma developing vaccines and monoclonal antibodies for resistant bacteria (e.g., against *S. aureus*, *C. difficile*, *P. aeruginosa*). Its differentiation lies in its specific immunomodulatory platform and focus on potentiating the host's natural immune response.